

Supplemental Figure 1. Distribution of ANA patterns by immunofluorescence (IIF) on HEp-2000 cells.



Abbreviations: CMP, cytoplasmic/mitotic pattern

Supplemental Figure 2. Distribution of cytoplasmic/mitotic patterns by

immunofluorescence (IIF) on HEp-2000 cells.



Abbreviations: CMP, cytoplasmic/mitotic pattern; AC-18, cytoplasmic dots; AC-19, diffuse cytoplasmic; AC-20, cytoplasmic speckled; AC-28, chromosome coat protein.

Demographic and Clinical Variables	Definition
Age	Years at diagnosis
Sex	Female or male
Post-secondary education	History of attendance at any time
Race/ethnicity	Asian: Chinese, Filipino, Japanese, Korean,
	others; African descendants: African,
	Caribbean; Hispanic: Hispanics only;
	Caucasian: North American, Indian – sub-
	continent, others; Other: Native North
	American, Native Hawaiian or other Pacific
	Islanders, others
Smoking status	Never smokers, current smoker, or former
	smokers, all mutually exclusive
High alcohol use	For females, high alcohol use was defined as
	more than 10 drinks a week and for males,
	more than 15 drinks a week (high-use or
	high-risk drinking based on current Canadian
	guidelines (49)).
Hypertension	Being on an anti-hypertensive medication or
	systolic blood pressure >140 or diastolic
	pressure >90

Supplemental Table 1. Clinically defined samples

Presence of nephritis	Based on renal biopsy or fulfillment of the
	renal item of the ACR Classification criteria
Presence of proteinuria	≥3g per day
American College of Rheumatology (ACR)	Number of specific ACR criteria fulfilled
criteria	
SLE Disease Activity Index (SLEDAI-2K)	Disease activity measured by global
score	SLEDAI-2K score and its individual
	components grouped to represent the
	following organ systems:
	Neurological: seizures, psychosis, organic
	brain syndrome, visual disturbance, cranial
	nerve disorder, lupus headache, CVA
	Mucocutaneous: vasculitis, rash, alopecia,
	mucosal ulcers
	Musculoskeletal: arthritis, myositis
	Renal: urinary casts, hematuria, proteinuria,
	pyuria
	Serositis: pleurisy, pericarditis
	Constitutional: fever
	Immunological: low complement, increased
	DNA binding
	Hematological: thrombocytopenia,
	leukopenia

MedicationsAny use of oral or parental glucocorticoids,
high dose glucocorticoids (pulse or
prednisone ≥40mg per day) antimalarials,
immunosuppressive agents (methotrexate,
azathioprine, mycophenolate,
cyclophosphamide, cyclosporine, and
biologics) at or prior to enrollment.

Supplemental Table 2. Univariable and multivariable analysis of demographic, clinical, and serologic profiles of anti-cellular antibody(ACA)-negative versus ANA-positive

	ACA- vs ANA +	
	Univariate model	Multivariate model
	Odds ratio	Odds ratio
	95% CI	95% CI
Age at diagnosis, year	1.03 (1.01, 1.05)*	1.02 (1, 1.04)*
Female, %	1.05 (0.47, 2.35)	
Post-secondary educ., % attended	1.59 (0.9, 2.84)	
Disease duration, years	0.65 (0.32, 1.32)	
Race/ethnicity, %		
Asian	0.15 (0.05, 0.47)*	
African descendants	0.39 (0.16, 0.99)*	
Hispanic	0.83 (0.2, 3.54)	
Caucasian	4.96 (2.58, 9.53)*	3.59 (1.8, 7.15)*
Other	0.28 (0.04, 2.08)	
Smoking status, %		
Current smoker	1.57 (0.85, 2.92)	
Former smoker	1.35 (0.76, 2.4)	
High alcohol use	1.03 (0.13, 7.88)	
Hypertension	0.87 (0.51, 1.47)	
Nephritis at enrollment, %	0.9 (0.51, 1.59)	

Proteinuria at enrollment, %	0.72 (0.17, 3.05)	
# ACR criteria, mean	0.89 (0.69, 1.14)	
SLEDAI-2K score, mean	0.94 (0.89, 1)*	
Neurological	1.03 (0.9, 1.18)	
Mucocutaneous	0.98 (0.85, 1.12)	
Musculoskeletal	0.98 (0.84, 1.14)	
Renal	0.91 (0.81, 1.01)	
Serositis	1.11 (0.71, 1.74)	
Constitutional	0.36 (0.05, 2.69)	
Immunological	0.82 (0.69, 0.96)*	
Hematological	0.4 (0.13, 1.25)	
Medications, % ever using		
Glucocorticoids	0.71 (0.41, 1.23)	
High doses of glucocorticoids	1.18 (0.73, 1.92)	2.41 (1.4, 4.15)*
Antimalarials	0.77 (0.46, 1.3)	
Immunosuppressants/biologics	0.41 (0.23, 0.71)*	0.35 (0.19, 0.65)*
Autoantibodies, %		
dsDNA	0.32 (0.15, 0.67)*	
PCNA	0.18 (0.02, 1.32)	
Ribosomal-P	0.31 (0.11, 0.86)*	
Ro52/TRIM21	0.48 (0.27, 0.86)*	
SSA/Ro60	0.32 (0.18, 0.57)*	0.41 (0.23, 0.73)*
SSB/La	0.32 (0.11, 0.88)*	

Sm	0.18 (0.07, 0.51)*	
U1-RNP	0.26 (0.13, 0.56)*	0.42 (0.19, 0.91)*
Lupus Anticoagulant	0.99 (0.53, 1.86)	
Anti-cardiolipin	0.87 (0.39, 1.95)	
Anti-B2glycoprotein1	1.07 (0.53, 2.14)	

*Denotes an odds ratio that is statistically significant

Abbreviations: ACR, American College of Rheumatology; ANA, anti-nuclear antibody; dsDNA, double stranded DNA; IIF, indirect immunofluorescence; PCNA, proliferating cell nuclear antigen; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; Sm, Smith (U2-U6 RNP); SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B; TRIM 21, tripartite motif 21; yr, years. Supplemental Table 3. Univariable and multivariable analysis of demographic, clinical, and serologic profiles of isolated CMP versus ANA-positive

	Isolated CMP vs ANA +	
	Univariate model	Multivariate model
	Odds ratio	Odds ratio
	95% CI	95% CI
Age at diagnosis, year	1.01 (0.97, 1.04)	
Female, %		
Post-secondary educ., % attended	0.23 (0.08, 0.66)*	0.25 (0.09, 0.73)*
Disease duration, years	0.34 (0.07, 1.59)	
Race/ethnicity, %		
Asian	0.44 (0.1, 1.94)	
African descendants	0.32 (0.04, 2.45)	
Hispanic		
Caucasian	2.95 (0.96, 9.11)	
Other	1.24 (0.16, 9.54)	
Smoking status, %		
Current smoker	1.3 (0.37, 4.61)	
Former smoker	1.25 (0.4, 3.9)	
High alcohol use		
Hypertension	2.95 (1.11, 7.83)*	3.14 (1.12, 8.77)*
Nephritis at enrollment, %	2.48 (0.92, 6.68)	
Proteinuria at enrollment, %	3.04 (0.67, 13.8)	

# ACR criteria, mean	0.92 (0.56, 1.49)
SLEDAI-2K score, mean	1 (0.91, 1.1)
Neurological	
Mucocutaneous	1.04 (0.82, 1.31)
Musculoskeletal	1.15 (0.89, 1.5)
Renal	1.03 (0.9, 1.18)
Serositis	
Constitutional	
Immunological	0.83 (0.6, 1.16)
Hematological	
Medications, % ever using	
Glucocorticoids	1.12 (0.32, 3.93)
High doses of glucocorticoids	1.95 (0.74, 5.15)
Antimalarials	0.39 (0.15, 1.02)
Immunosuppressants/biologics	1.84 (0.7, 4.88)
Autoantibodies, %	
dsDNA	0.54 (0.15, 1.89)
PCNA	1.68 (0.38, 7.49)
Ribosomal-P	0.69 (0.16, 3.06)
Ro52/TRIM21	0.55 (0.18, 1.69)
SSA/Ro60	0.46 (0.16, 1.33)
SSB/La	0.7 (0.16, 3.11)
Sm	0.41 (0.09, 1.79)

U1-RNP	0.28 (0.06, 1.22)	
Lupus Anticoagulant	0.27 (0.04, 2.08)	
Anti-cardiolipin	0.99 (0.22, 4.42)	
Anti-B2glycoprotein1	0.81 (0.18, 3.59)	

*Denotes an odds ratio that is statistically significant

Abbreviations: ACR, American College of Rheumatology; ANA, anti-nuclear antibody; dsDNA, double stranded DNA; IIF, indirect immunofluorescence; PCNA, proliferating cell nuclear antigen; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; Sm, Smith (U2-U6 RNP); SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B; TRIM 21, tripartite motif 21; yr, years.

	Isolated CMP vs ACA -	
	Univariate model Multivariate mode	
	Odds ratio	Odds ratio
	95% CI	95% CI
Age at diagnosis, year	0.97 (0.93, 1.01)	
Female, %		
Post-secondary educ., % attended	0.14 (0.04, 0.47)*	0.13 (0.04, 0.46)*
Disease duration, years	0.54 (0.1, 2.86)	
Race/ethnicity, %		
Asian	3.02 (0.46, 19.7)	
African descendants	0.83 (0.09, 7.56)	
Hispanic		
Caucasian	0.6 (0.16, 2.17)	
Other	4.38 (0.26, 73.73)	
Smoking status, %		
Current smoker	0.82 (0.21, 3.3)	
Former smoker	0.92 (0.26, 3.25)	
High alcohol use		
Hypertension	3.4 (1.14, 10.14)*	4.13 (1.18, 14.48)*
Nephritis at enrollment, %	2.76 (0.9, 8.53)	
Proteinuria at enrollment, %	4.21 (0.55, 32.56)	

Supplemental Table 4. Univariable and multivariable analysis of demographic, clinical, and serologic profiles of isolated CMP versus anti-cellular antibody(ACA)-negative

# ACR criteria, mean	1.04 (0.57, 1.9)	
SLEDAI-2K score, mean	1.06 (0.95, 1.19)	
Neurological		
Mucocutaneous	1.1 (0.77, 1.57)	
Musculoskeletal	1.19 (0.88, 1.61)	
Renal	1.13 (0.95, 1.34)	
Serositis		
Constitutional		
Immunological	1.02 (0.71, 1.46)	
Hematological		
Medications, % ever using		
Glucocorticoids	1.58 (0.41, 6.16)	
High doses of glucocorticoids	1.65 (0.56, 4.81)	
Antimalarials	0.51 (0.17, 1.48)	
Immunosuppressants/biologics	4.54 (1.5, 13.76)*	
Autoantibodies, %		
dsDNA	1.69 (0.4, 7.18)	
PCNA	9.33 (0.79, 109.72)	
Ribosomal-P	2.23 (0.37, 13.34)	
Ro52/TRIM21	1.15 (0.33, 4.04)	
SSA/Ro60	1.43 (0.44, 4.67)	
SSB/La	2.23 (0.37, 13.34)	
Sm	2.2 (0.37, 13.14)	

U1-RNP	1.05 (0.2, 5.46)	
Lupus Anticoagulant	0.27 (0.03, 2.29)	
Anti-cardiolipin	1.14 (0.21, 6.11)	
Anti-ß2glycoprotein1	0.76 (0.15, 3.86)	

*Denotes an odds ratio that is statistically significant

Abbreviations: ACR, American College of Rheumatology; ANA, anti-nuclear antibody; dsDNA, double stranded DNA; IIF, indirect immunofluorescence; PCNA, proliferating cell nuclear antigen; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; Sm, Smith (U2-U6 RNP); SSA, Sjögren's syndrome antigen A; SSB, Sjögren's syndrome antigen B; TRIM 21, tripartite motif 21; yr, years.